WHO working group drafts resolution on SSFFC drugs

Published: 7-Nov-2011
Regulatory

Creates a mechanism for international collaboration among World Health Assembly members


The World Health Organization’s working group on low-quality and illegal medicines has drawn up a draft resolution for debate at the 65th World Health Assembly in May 2012.

The draft document backs the WHO’s role in ensuring the public’s access to safe, effective and affordable medicines of acceptable quality, but indicates that the agency should take a back seat on the topic of what have become known as substandard/spurious/falsely labelled/falsified/counterfeit (SSFFC) medical products.

The resolution would create a mechanism for international collaboration among World Health Assembly member states on the topic of SSFFCs to protect public health.

The WHO would continue to share information, create awareness, set standards and provide technical assistance to national governments.

The member state mechanism would identify major needs and challenges in the area of SSFFCs, make policy recommendations and develop tools for the prevention, detection and control of these products.

No progress has been made on finding a solution to the nomenclature of SSFFCs.

  • Companies:
  • World Health Organization
See more

You may also like

Personal Protection

Containment: key to tackling coronavirus outbreak

Read more
China and WHO authorities agreed that further studies on the severity and transmissibility of the virus are needed and immediate communication of any findings is crucial

Trending Articles

  1. Accelerating and enhancing toxicology assessments Infographic guides users through ToxHQ’s speedy assessment features
  2. You need to be a subscriber to read this article.
    Click here to find out more.
    Merck jumps on the GLP-1 therapeutic bandwagon by licensing Hansoh Pharma's HS-10535 Merck will be responsible for the development, manufacture and commercialisation of the investigational preclinical oral GLP-1 receptor agonist
  3. Bayer's acoramidis recommended for approval by the EMA's CHMP for cardiomyopathy The orally administered transthyretin (TTR) stabiliser is suitable for patients with transthyretin amyloid cardiomyopathy, demonstrating at least a 90% TTR stabilisation capacity and a reduction in cardiovascular-related hospitalisations
  4. You need to be a subscriber to read this article.
    Click here to find out more.
    Why quality control should be intimately combined with sterile product development, manufacturing and the overall product supply chain With sponsor companies increasingly needing to create and launch differentiated, stable, usable and safe injectable treatments for patients, experts at ten23 health are keen to promote the importance of integrating development and/or manufacturing with quality control services
  5. The right validation model: practical considerations and applications It is widely accepted that validation in the life sciences industry follows a lifecycle model (1,2). What is not always clear is the specific model — or models — to follow and how to navigate through them in the real world. Hurdles to overcome include the specific deliverables that make up that model and how they change during the various interactions along the validation journey

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

You may also like

Personal Protection

Containment: key to tackling coronavirus outbreak

China and WHO authorities agreed that further studies on the severity and transmissibility of the virus are needed and immediate communication of any findings is crucial
Regulatory

WHO proposes central registry on human genome editing research

On the heels of the Chinese CRISPR scandal, stakeholders in the genome editing industry will be consulted to create standards for future research
Regulatory

Annex 1 harmonisation moves a step closer

Revision to Annex 1 on the manufacturing of sterile medicinal products of the PIC/S – EU GMP Guide goes out for joint stakeholder consultation
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

EU considers endocrine disrupter controls

It has long been known that pharmaceutical residues can become hormone-affecting ‘endocrine disrupters’ when released into the environment and future controls are likely – but how will the legislators tackle the issue? Manufacturing Chemist reports
Regulatory

India Pharmacopoeia Commission joins WHO network

India has set up 179 centres to monitor adverse drug reactions across the country
Regulatory

European Commission, EMA and WHO step up co-operation to protect global public health

New working arrangement will allow timely sharing of non-public information
Regulatory

Vietnamese national regulatory authority meets international standards for vaccine regulation

The World Health Organisation has formally certified that Vietnam has a fully equipped national regulatory system that ensures the safety and efficacy of vaccines produced and used in the country
Subscribe now